|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Investing
Activities
Net cash used in investing activities was $62.8 million in
the first half of 2009. The primary components of cash used in
investing activities were capital expenditures of
$83.9 million offset by proceeds of $10.6 million from
the disposal of
available-for-sale
investments. Included within capital expenditures was a
$50.0 million optional payment made to Biogen Idec in order
to maintain an approximate 50% share of Tysabri for
annual global in-market net sales of Tysabri that are in
excess of $1.1 billion.
Net cash provided by investing activities was
$187.8 million in the first half of 2008. The primary
components of cash provided by investing activities were the
proceeds of $205.2 million from the disposal of
available-for-sale
investments, principally relating to the liquidation of an
investment in a fund that had been reclassified from cash
equivalents to investments in December 2007 due to dislocations
in the capital markets, offset by capital expenditures of
$23.2 million.
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Investing
Activities
Net cash provided by investing activities was $94.5 million
in 2008. The primary components of cash provided by investing
activities were proceeds of $236.1 million from the sale of
available-for-sale
investments, principally relating to the liquidation of an
investment in a fund that had been reclassified from cash
equivalents to investments in December 2007 due to dislocations
in the capital markets, and capital expenditure of
$137.9 million. Included within capital expenditures was a
$75.0 million optional payment made to Biogen Idec in order
to maintain an approximate 50% share of Tysabri for
annual global in-market net sales of Tysabri that are in
excess of $700.0 million.
Table of Contents
Financial Review
Net cash used in investing activities was $326.6 million in
2007. The primary component of cash used in investing activities
was a transfer of $305.9 million relating to the fund that
was reclassified from cash equivalents to investments in
December 2007.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Investing
Activities
Net cash provided by investing activities was $94.5 million
in 2008. The primary components of cash provided by investing
activities were proceeds of $236.1 million from the sale of
investment securities, principally relating to the liquidation
of an investment in a fund that had been reclassified from cash
equivalents to investments in December 2007 due to dislocations
in the capital markets, and capital expenditure of
$137.9 million. Included within capital expenditures was a
$75.0 million optional payment made to Biogen Idec in order
to maintain an approximate 50% share of Tysabri for
annual global in-market net sales of Tysabri that are in
excess of $700.0 million.
Net cash used in investing activities was $318.1 million in
2007. The primary component of cash used in investing activities
was a transfer of $305.9 million relating to the fund that
was reclassified from cash equivalents to investments in
December 2007. Net cash provided by investing activities was
$37.5 million in 2006. The major components of cash
generated from investing activities were net proceeds of
$14.1 million from the sale of investment securities and
$54.2 million from the sale of the European rights to
Prialt (net of transaction costs), partially offset by
$34.0 million for capital expenditures.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
